ADCb
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ADCb, covering 2021-07-27 to 2021-07-27. Get the full timeline:
Most recent: Clinical Trial Update: ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer [Phase 2]